Breadcrumb

[A14-12] Canagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Overview

Overview

Commission: Commission awarded on 2014-03-14 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 347 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A14-24] Addendum to Commission A14-12 (canagliflozin)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2014-06-16 Extract of dossier assessment 347 kBPDFdownload file
2014-06-16 Dossier assessment (German version) 655 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Canagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) [PDF, 347 kB]

Federal Joint Committee (G-BA)

2014-09-04 A G-BA decision was published.

G-BA documents on this decision

Press releases

2014-06-16 Type 2 diabetes mellitus: Added benefit of canagliflozin is not proven



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close